IMMU:NSD-Immunomedics, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 8.94

Change

0.00 (0.00)%

Market Cap

USD 20.31B

Volume

0.24M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict


Immunomedics, Inc (IMMU) Stock Analysis:
Based on the Immunomedics, Inc stock forecasts from 0 analysts, the average analyst target price for Immunomedics, Inc is not available over the next 12 months. Immunomedics, Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Immunomedics, Inc is Very Bearish, which is based on 0 positive signals and 1 negative signals. At the last closing, Immunomedics, Inc’s stock price was USD 8.94. Immunomedics, Inc’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +0.00% over the last year.

No recent analyst target price found for Immunomedics, Inc
No recent average analyst rating found for Immunomedics, Inc

About

Immunomedics, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. It develops sacituzumab govitecan, an antibody-drug conjugate for the treatment of patients with metastatic triple-negative breast can ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-01-25 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna Inc

-4.76 (-3.03%)

USD67.92B 10.04 12.33
REGN Regeneron Pharmaceuticals Inc

-18.29 (-2.94%)

USD66.83B 9.94 8.23
VRTX Vertex Pharmaceuticals Incorpo..

-2.57 (-1.12%)

USD57.63B 27.19 15.97
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
BNTX BioNTech SE

+5.51 (+3.65%)

USD36.62B 4.77 5.67
BGNE BeiGene Ltd

-15.38 (-6.18%)

USD25.75B N/A N/A
SGEN Seagen Inc

-4.45 (-3.43%)

USD23.69B 55.02 44.86
GMAB Genmab A/S

-1.55 (-4.54%)

USD22.21B 50.69 6.21
RPRX Royalty Pharma plc

-0.34 (-0.86%)

USD16.38B 19.81 11.89
INCY Incyte Corporation

-1.19 (-1.58%)

USD16.32B 30.62 21.11

ETFs Containing IMMU

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain 95.09% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 95.09% N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 45.16% N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 45.16% N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 121.30% N/A N/A N/A N/A
Risk Adjusted Return 37.23% N/A N/A N/A N/A
Market Capitalization 20.31B N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 34.23 N/A N/A N/A N/A
Price / Cash Flow Ratio -91.30 N/A N/A N/A N/A
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -68.78% N/A N/A N/A N/A
Return on Assets -25.16% N/A N/A N/A N/A
Debt to Equity Ratio 96.09% N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.15 N/A N/A N/A N/A
Short Percent 8.66% N/A N/A N/A N/A
Beta 2.90 N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.